329 related articles for article (PubMed ID: 19636247)
1. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
Singh M; Arora R; Jawad E
Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
Ahmad K; Dorian P
Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
[TBL] [Abstract][Full Text] [Related]
4. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
6. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
7. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
8. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
9. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
Ly T; Ruiz ME
Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ; Roden DM
Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
Shantsila E; Watson T; Lip GY
Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
[TBL] [Abstract][Full Text] [Related]
12. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
Milberg P; Eckardt L; Bruns HJ; Biertz J; Ramtin S; Reinsch N; Fleischer D; Kirchhof P; Fabritz L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Oct; 303(1):218-25. PubMed ID: 12235254
[TBL] [Abstract][Full Text] [Related]
13. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
14. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
[TBL] [Abstract][Full Text] [Related]
16. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
Kecskeméti V
Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
[TBL] [Abstract][Full Text] [Related]
17. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
Hondeghem LM
J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
[TBL] [Abstract][Full Text] [Related]
18. Long QT syndrome and short QT syndrome.
Zareba W; Cygankiewicz I
Prog Cardiovasc Dis; 2008; 51(3):264-78. PubMed ID: 19026859
[TBL] [Abstract][Full Text] [Related]
19. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
[TBL] [Abstract][Full Text] [Related]
20. Cardiac K+ channels and drug-acquired long QT syndrome.
Drici MD; Barhanin J
Therapie; 2000; 55(1):185-93. PubMed ID: 10860023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]